XTalks

DECEMBER 5, 2023

Augtyro, a tyrosine kinase inhibitor (TKI), is available as oral capsules, each containing 40 mg of repotrectinib. Analysts at William Blair estimate that Augtyro’s sales could climb to $258 million by 2027, contingent on its anticipated approval in Europe next year.

Protein 115

Protein FDA Approval Medicine Trials 115

The Pharma Data

JANUARY 7, 2021

The Company also has granted to the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the Public Offering Price to cover over-allotments in the sales of the securities, if any. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. About Cerecor Inc.

Sales 52

Sales Clinical Development Development Containment 52

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration (“FDA”) approval.

Drugs 52

Drugs Containment Development Sales 52

The Pharma Data

JANUARY 21, 2021

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 52

Containment Sales Production Development 52

The Pharma Data

DECEMBER 27, 2020

Gritstone Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; and the timing and expectation of the closing of the additional PIPE financing. For more information, please visit gritstoneoncology.com.

Sales 52

Sales Development Manufacturing Life Science 52

XTalks

NOVEMBER 9, 2023

Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. billion in just one year and a quarter. billion for Novo.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

The Pharma Data

JULY 15, 2021

Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars , including 100 million dollars in upfront and near-term clinical milestone payments Novo Nordisk will develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy.

Antibody 52

Antibody Sales Protein Development 52

The Pharma Data

JANUARY 19, 2021

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Gene Expression 40

Gene Expression Containment Genetics Sales 40

The Pharma Data

OCTOBER 27, 2020

Mirati will not receive any proceeds from the sale of common stock by the selling stockholder. Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. This press release contains forward-looking statements within the meaning of the U.S.

Sales 52

Sales Immune Response Clinical Development Development 52

The Pharma Data

JANUARY 26, 2021

The Registration Statement also contains a preliminary prospectus supplement relating to an “at-the-market” sales agreement, which the Company expects to enter into with B. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. capital markets. Riley Securities, Inc.

Life Science 40

Life Science Sales Antibody Marketing 40

The Pharma Data

JANUARY 24, 2021

. The Company currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures. About Citius Pharmaceuticals, Inc. .

Marketing 40

Marketing Production Sales Containment 40

Pharmaceutical Technology

NOVEMBER 25, 2022

In many cases, pharma companies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. In one specific case, Cambrex developed a PDF containing two APIs in suspension in an 80/20 ratio.

Manufacturing 130

Manufacturing Production Pharma Companies Development 130

The Pharma Data

DECEMBER 16, 2020

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Sales 52

Sales Containment Clinical Development Marketing 52

pharmaphorum

OCTOBER 2, 2020

COMP360 is a crystalline formulation of psilocybin in phase 2b clinical development in patients who have not responded to standard therapy for depression. Compass has a patented synthetic version of psilocybin, the active ingredient in magic mushrooms, and raised around $127.5 million with its IPO shortly after the announcement.

Medicine 110

Medicine Life Science FDA Approval Development 110

The Pharma Data

JANUARY 20, 2021

The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX expects to use any remaining net proceeds from this offering for capital expenditures, working capital and other general corporate purposes.

Clinical Development 40

Clinical Development Development Sales Antibody 40

The Pharma Data

DECEMBER 14, 2020

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Clinical Trials 40

Clinical Trials Clinical Trials Clinical Development Antibody 40

The Pharma Data

JANUARY 27, 2021

. A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies. ET ) to discuss the results and next steps in clinical development of BI-1206.

Antibody 52

Antibody Containment Development Trials 52

The Pharma Data

NOVEMBER 4, 2020

. Juyou will be responsible for the overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the “NMPA”, formerly the China State Food and Drug Administration). million and US$1.8 About Juyou Bio – Technology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

JANUARY 12, 2021

The FDA Fast Track program is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements.

Trials 52

Trials Containment Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 1, 2020

Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1b multiple-ascending dose study and a Phase 2 proof-of-concept study planned for 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Development 52

The Pharma Data

DECEMBER 15, 2020

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 40

Containment Sales FDA Approval Development 40

The Pharma Data

SEPTEMBER 16, 2020

Amgen’s clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C ?inhibitor Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen.

Production 52

Production Sales Clinical Trials Clinical Trials 52

Delveinsight

JULY 27, 2021

Expanded Approval in GSK’s Pocket for Shingles Expected to Generate High Sales. In 2019 as the uptake increased, Shingrix sales double folded. This globalized COVID-19 vaccine supply chain and manufacturing network, incorporates 3 continents and will contain around 20 manufacturing facilities. gingivalis. billion people.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

The Pharma Data

JANUARY 25, 2021

The sale of the notes is expected to close on January 28, 2021, subject to customary closing conditions. over the last reported sale price of the Company’s common stock of $65.79 per share, which represents a premium of 100% over the last reported sale price of the Company’s common stock of $65.79 per share on January 25, 2021.

Sales 52

Sales Marketing Containment Development 52

The Pharma Data

NOVEMBER 23, 2020

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com. . . View original content to download multimedia: [link].

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

SEPTEMBER 20, 2020

Amgen’s clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C ?inhibitor Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen.

Medicine 52

Medicine Production Sales Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

Govindarajan, Managing Director, Aurobindo Pharma Limited , said: “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” ” .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

JANUARY 20, 2021

INOVIO intends to use the net proceeds from this offering for the development of its clinical pipeline, including clinical development expenses relating to INO-4800 and research and development expenses, and for general corporate purposes, including working capital and general and administrative expenses.

DNA 40

DNA Containment Immune Response Sales 40

pharmaphorum

SEPTEMBER 8, 2022

billion acquisition of Endocyte in 2018 , with estimations that sales could reach $600 million in this first indication alone. The diagnostic products containing Cu-64 have a shelf-life of several days, allowing central manufacture and regional distribution, potentially reaching more treatment centres and patients,” Taylor outlined.

Manufacturing 96

Manufacturing Development Drugs Antibody 96

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Sales 40

The Pharma Data

JANUARY 20, 2021

Chimerix intends to use the net proceeds from the proposed offering to fund the clinical development of its product candidates, commercial pre-launch activities and general corporate purposes. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Sales 52

The Pharma Data

JULY 6, 2021

The demerger structure reflects feedback from a significant proportion of GSK’s shareholders that they wish to own Consumer Healthcare as a new listed entity, given its strong prospects for sustainable sales and profit growth, high cash generation and the expectation that it will deliver attractive returns for shareholders.

Sales 52

Sales Vaccination Vaccine Production 52

The Pharma Data

JANUARY 27, 2021

The Company is in late-stage clinical development and has been working toward establishing commercial readiness. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. About MultiStem ®. Forward-Looking Statements.

Clinical Trials 52

Clinical Trials Clinical Trials Production Trials 52

The Pharma Data

NOVEMBER 3, 2020

Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.

Clinical Trials 52

Clinical Trials Clinical Trials Production FDA Approval 52

Drug Discovery World

MARCH 29, 2023

Peter O’Donnell, Applied Clinical Trials’ Brussels Correspondent, summarises this as the EMA being tasked with creating a European network of patient representatives, academics, drug developers, investigators, and centres with expertise in the performance of studies in the paediatric population.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

The Pharma Data

NOVEMBER 5, 2020

net sales increased 11% to $1.32 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 “This is evidenced by Dupixent achieving in excess of $1 billion in global net sales this quarter.” Updates from the clinical pipeline include: Dupixent ® (dupilumab).

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

OCTOBER 28, 2020

Free cash flow , which also reflects capital expenditures and proceeds from asset sales, was JPY 425.5 billion in reported revenue represented 24% of sales, spearheaded by exceptional growth through expanded patient share of gut-selective ENTYVIO in the U.S., Takeda’s reported net profit was JPY 86.5 billion, a 15.8% to JPY 392.0

Sales 40

Sales Production Engineer Development 40